| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Photochemotherapy | 31 | 2020 | 96 | 4.810 |
Why?
|
| Radiation Oncology | 23 | 2021 | 529 | 3.190 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 34 | 2020 | 5319 | 2.010 |
Why?
|
| Photosensitizing Agents | 13 | 2020 | 71 | 1.940 |
Why?
|
| Proton Therapy | 18 | 2019 | 1577 | 1.920 |
Why?
|
| Lung Neoplasms | 47 | 2020 | 11538 | 1.850 |
Why?
|
| Metalloporphyrins | 10 | 2008 | 30 | 1.820 |
Why?
|
| Cyclic N-Oxides | 16 | 2004 | 106 | 1.620 |
Why?
|
| Radiosurgery | 17 | 2020 | 1330 | 1.410 |
Why?
|
| Radiation-Protective Agents | 11 | 2013 | 128 | 1.240 |
Why?
|
| Nelfinavir | 7 | 2018 | 15 | 1.050 |
Why?
|
| Pleural Neoplasms | 9 | 2016 | 470 | 1.020 |
Why?
|
| Neoplastic Cells, Circulating | 7 | 2020 | 607 | 0.980 |
Why?
|
| Prostatic Neoplasms | 15 | 2016 | 5767 | 0.960 |
Why?
|
| Neoplasms | 34 | 2021 | 15193 | 0.900 |
Why?
|
| Dihematoporphyrin Ether | 7 | 2006 | 15 | 0.810 |
Why?
|
| Quality Improvement | 4 | 2016 | 851 | 0.750 |
Why?
|
| Alkyl and Aryl Transferases | 8 | 2005 | 87 | 0.730 |
Why?
|
| Safety Management | 3 | 2016 | 132 | 0.730 |
Why?
|
| Peritoneal Neoplasms | 7 | 2020 | 821 | 0.720 |
Why?
|
| Mesothelioma | 8 | 2016 | 544 | 0.700 |
Why?
|
| HIV Protease Inhibitors | 4 | 2013 | 72 | 0.700 |
Why?
|
| Radiotherapy, Intensity-Modulated | 8 | 2019 | 2104 | 0.700 |
Why?
|
| Telomerase | 6 | 2020 | 525 | 0.680 |
Why?
|
| Diagnostic Imaging | 4 | 2018 | 1162 | 0.670 |
Why?
|
| Combined Modality Therapy | 25 | 2019 | 8865 | 0.650 |
Why?
|
| Radiation Tolerance | 11 | 2019 | 629 | 0.630 |
Why?
|
| Hemoglobins | 3 | 2018 | 477 | 0.620 |
Why?
|
| Sarcoma | 10 | 2020 | 1725 | 0.620 |
Why?
|
| Etanidazole | 10 | 2012 | 12 | 0.620 |
Why?
|
| Risk Management | 2 | 2015 | 107 | 0.610 |
Why?
|
| Hematoporphyrin Photoradiation | 4 | 2005 | 4 | 0.600 |
Why?
|
| Humans | 166 | 2021 | 261506 | 0.600 |
Why?
|
| Administrative Personnel | 4 | 2019 | 35 | 0.580 |
Why?
|
| Chemoradiotherapy | 6 | 2019 | 1946 | 0.570 |
Why?
|
| Hydrocarbons, Fluorinated | 10 | 2012 | 26 | 0.560 |
Why?
|
| Radiation, Ionizing | 1 | 2016 | 187 | 0.540 |
Why?
|
| Insurance Coverage | 2 | 2018 | 256 | 0.540 |
Why?
|
| Hospital Departments | 1 | 2015 | 15 | 0.530 |
Why?
|
| Organs at Risk | 2 | 2015 | 514 | 0.520 |
Why?
|
| Antioxidants | 6 | 2003 | 507 | 0.520 |
Why?
|
| ras Proteins | 5 | 2008 | 770 | 0.520 |
Why?
|
| Galectin 1 | 1 | 2014 | 20 | 0.510 |
Why?
|
| Radiation-Sensitizing Agents | 9 | 2018 | 363 | 0.500 |
Why?
|
| Radiotherapy | 9 | 2019 | 1824 | 0.500 |
Why?
|
| State Health Plans | 1 | 2014 | 8 | 0.500 |
Why?
|
| Health Planning | 1 | 2014 | 26 | 0.490 |
Why?
|
| Financing, Government | 1 | 2014 | 40 | 0.480 |
Why?
|
| Aged | 70 | 2020 | 70117 | 0.480 |
Why?
|
| Cell Hypoxia | 10 | 2013 | 328 | 0.480 |
Why?
|
| Spin Labels | 16 | 2004 | 76 | 0.480 |
Why?
|
| Male | 94 | 2020 | 123000 | 0.470 |
Why?
|
| Light | 6 | 2010 | 245 | 0.460 |
Why?
|
| Patient Safety | 2 | 2016 | 649 | 0.460 |
Why?
|
| Direct Service Costs | 1 | 2012 | 12 | 0.450 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 598 | 0.440 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 6 | 2018 | 2370 | 0.440 |
Why?
|
| Urogenital System | 1 | 2012 | 59 | 0.440 |
Why?
|
| Middle Aged | 73 | 2020 | 86204 | 0.440 |
Why?
|
| Radioimmunotherapy | 1 | 2013 | 119 | 0.440 |
Why?
|
| Anemia | 2 | 2018 | 689 | 0.430 |
Why?
|
| Precision Medicine | 2 | 2017 | 1154 | 0.430 |
Why?
|
| Health Care Costs | 3 | 2015 | 674 | 0.430 |
Why?
|
| Head and Neck Neoplasms | 6 | 2015 | 3976 | 0.430 |
Why?
|
| Oxygen | 10 | 2009 | 754 | 0.430 |
Why?
|
| Lymphopenia | 1 | 2014 | 199 | 0.430 |
Why?
|
| Needs Assessment | 2 | 2016 | 233 | 0.410 |
Why?
|
| Neoplasm Staging | 25 | 2020 | 13658 | 0.410 |
Why?
|
| Patient Selection | 3 | 2020 | 2055 | 0.410 |
Why?
|
| Drug Resistance, Multiple | 2 | 2005 | 204 | 0.400 |
Why?
|
| Female | 95 | 2020 | 141928 | 0.400 |
Why?
|
| Health Policy | 1 | 2014 | 291 | 0.390 |
Why?
|
| Neoplasm Recurrence, Local | 16 | 2020 | 10035 | 0.390 |
Why?
|
| Tumor Microenvironment | 4 | 2019 | 2864 | 0.380 |
Why?
|
| Medical Oncology | 2 | 2017 | 1423 | 0.370 |
Why?
|
| Algorithms | 5 | 2014 | 3890 | 0.370 |
Why?
|
| Antineoplastic Agents | 18 | 2020 | 14289 | 0.360 |
Why?
|
| Imidazoles | 4 | 2004 | 999 | 0.350 |
Why?
|
| Prostate | 5 | 2008 | 1088 | 0.350 |
Why?
|
| Academic Medical Centers | 3 | 2019 | 672 | 0.350 |
Why?
|
| Medicare | 1 | 2014 | 860 | 0.340 |
Why?
|
| Radiobiology | 3 | 2015 | 56 | 0.340 |
Why?
|
| Treatment Outcome | 34 | 2020 | 32848 | 0.340 |
Why?
|
| Evidence-Based Medicine | 2 | 2014 | 1085 | 0.340 |
Why?
|
| Animals | 54 | 2020 | 59536 | 0.340 |
Why?
|
| Health Services Accessibility | 2 | 2015 | 761 | 0.340 |
Why?
|
| Sex Factors | 4 | 2019 | 2139 | 0.330 |
Why?
|
| Pneumonectomy | 8 | 2017 | 831 | 0.330 |
Why?
|
| Radiation Pneumonitis | 4 | 2019 | 301 | 0.330 |
Why?
|
| Doxorubicin | 4 | 2003 | 3005 | 0.330 |
Why?
|
| Adenocarcinoma | 7 | 2018 | 7789 | 0.330 |
Why?
|
| Geriatrics | 1 | 2009 | 98 | 0.330 |
Why?
|
| Radiation Injuries | 7 | 2017 | 1411 | 0.320 |
Why?
|
| Macular Degeneration | 1 | 2009 | 114 | 0.310 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2015 | 2594 | 0.310 |
Why?
|
| Clinical Trials as Topic | 9 | 2020 | 3719 | 0.310 |
Why?
|
| Bone Morphogenetic Protein 2 | 2 | 2018 | 142 | 0.300 |
Why?
|
| Enzyme Inhibitors | 6 | 2008 | 1879 | 0.300 |
Why?
|
| Brain Neoplasms | 9 | 2015 | 4849 | 0.290 |
Why?
|
| Adult | 47 | 2020 | 77950 | 0.290 |
Why?
|
| Biomarkers, Tumor | 7 | 2016 | 10331 | 0.290 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2009 | 272 | 0.280 |
Why?
|
| Neoplasms, Experimental | 6 | 2010 | 750 | 0.280 |
Why?
|
| Peer Review, Health Care | 2 | 2016 | 30 | 0.280 |
Why?
|
| Follow-Up Studies | 19 | 2018 | 14889 | 0.270 |
Why?
|
| Superoxide Dismutase | 4 | 1999 | 266 | 0.270 |
Why?
|
| Antibodies, Monoclonal | 3 | 2016 | 4367 | 0.270 |
Why?
|
| Carcinoma, Squamous Cell | 7 | 2017 | 5437 | 0.270 |
Why?
|
| Aged, 80 and over | 29 | 2020 | 29902 | 0.270 |
Why?
|
| Thoracic Neoplasms | 2 | 2020 | 337 | 0.270 |
Why?
|
| Dose-Response Relationship, Drug | 13 | 2013 | 4938 | 0.260 |
Why?
|
| Apoptosis | 4 | 2014 | 7591 | 0.260 |
Why?
|
| Faculty, Medical | 3 | 2019 | 289 | 0.260 |
Why?
|
| Personnel Selection | 2 | 2018 | 87 | 0.260 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2005 | 74 | 0.260 |
Why?
|
| Molecular Targeted Therapy | 2 | 2016 | 2330 | 0.260 |
Why?
|
| Porphyrins | 2 | 2020 | 37 | 0.250 |
Why?
|
| Biological Transport | 2 | 2010 | 597 | 0.250 |
Why?
|
| Cell Survival | 11 | 2005 | 3045 | 0.250 |
Why?
|
| Radiotherapy Dosage | 11 | 2019 | 3842 | 0.240 |
Why?
|
| Pleura | 3 | 2012 | 127 | 0.240 |
Why?
|
| Mice, Inbred C3H | 10 | 2010 | 385 | 0.240 |
Why?
|
| Alopecia | 1 | 2004 | 126 | 0.240 |
Why?
|
| Stromal Cells | 2 | 2019 | 825 | 0.240 |
Why?
|
| Farnesyltranstransferase | 8 | 2005 | 122 | 0.240 |
Why?
|
| Hydroxybenzoates | 1 | 2003 | 4 | 0.240 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2003 | 58 | 0.230 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2005 | 299 | 0.230 |
Why?
|
| Nitrogen Oxides | 4 | 1998 | 15 | 0.230 |
Why?
|
| Global Health | 2 | 2020 | 657 | 0.230 |
Why?
|
| Academies and Institutes | 2 | 2015 | 95 | 0.220 |
Why?
|
| Survival Analysis | 9 | 2019 | 9180 | 0.220 |
Why?
|
| Drug Monitoring | 1 | 2004 | 333 | 0.220 |
Why?
|
| Survival Rate | 14 | 2020 | 12221 | 0.210 |
Why?
|
| Paclitaxel | 5 | 2017 | 1996 | 0.210 |
Why?
|
| Daunorubicin | 1 | 2003 | 301 | 0.210 |
Why?
|
| Indicators and Reagents | 4 | 2007 | 128 | 0.210 |
Why?
|
| Burnout, Professional | 2 | 2017 | 205 | 0.210 |
Why?
|
| Dimethylallyltranstransferase | 3 | 2008 | 7 | 0.210 |
Why?
|
| Cost-Benefit Analysis | 3 | 2015 | 945 | 0.210 |
Why?
|
| United States | 14 | 2019 | 15433 | 0.210 |
Why?
|
| Mediastinal Neoplasms | 2 | 2016 | 423 | 0.200 |
Why?
|
| Free Radical Scavengers | 3 | 1998 | 80 | 0.200 |
Why?
|
| Disease Progression | 7 | 2020 | 6682 | 0.200 |
Why?
|
| Noncommunicable Diseases | 1 | 2021 | 15 | 0.200 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2003 | 156 | 0.200 |
Why?
|
| Re-Irradiation | 3 | 2017 | 163 | 0.200 |
Why?
|
| Hydrogen Peroxide | 4 | 1997 | 217 | 0.200 |
Why?
|
| Rectal Neoplasms | 1 | 2009 | 1202 | 0.190 |
Why?
|
| Immunotherapy | 5 | 2018 | 3341 | 0.190 |
Why?
|
| Fluorine Radioisotopes | 2 | 2012 | 133 | 0.190 |
Why?
|
| Glioblastoma | 5 | 2013 | 1797 | 0.190 |
Why?
|
| Hydroxylamines | 1 | 2000 | 8 | 0.190 |
Why?
|
| Pancreatic Neoplasms | 5 | 2018 | 5061 | 0.190 |
Why?
|
| Cancer Care Facilities | 2 | 2016 | 884 | 0.180 |
Why?
|
| Salvage Therapy | 3 | 2018 | 2054 | 0.180 |
Why?
|
| Thinking | 1 | 2020 | 33 | 0.180 |
Why?
|
| Blood Pressure | 3 | 2004 | 1467 | 0.180 |
Why?
|
| Time Factors | 14 | 2018 | 12926 | 0.180 |
Why?
|
| Cetuximab | 2 | 2020 | 472 | 0.180 |
Why?
|
| Specialty Boards | 2 | 2018 | 46 | 0.180 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2019 | 1249 | 0.180 |
Why?
|
| Dose-Response Relationship, Radiation | 6 | 2015 | 726 | 0.170 |
Why?
|
| Androgen Antagonists | 2 | 2015 | 411 | 0.170 |
Why?
|
| Registries | 3 | 2018 | 2170 | 0.170 |
Why?
|
| Pennsylvania | 3 | 2015 | 64 | 0.170 |
Why?
|
| Dogs | 5 | 2020 | 1155 | 0.170 |
Why?
|
| Recurrence | 3 | 2018 | 4758 | 0.170 |
Why?
|
| Dacarbazine | 2 | 2013 | 485 | 0.160 |
Why?
|
| Mentors | 1 | 2020 | 203 | 0.160 |
Why?
|
| Hemodynamics | 2 | 2000 | 935 | 0.160 |
Why?
|
| Tumor Burden | 4 | 2018 | 1987 | 0.160 |
Why?
|
| Skin Neoplasms | 2 | 2018 | 4654 | 0.160 |
Why?
|
| Hepcidins | 1 | 2018 | 34 | 0.160 |
Why?
|
| Efficiency, Organizational | 2 | 2015 | 88 | 0.160 |
Why?
|
| Gastrointestinal Neoplasms | 4 | 2006 | 600 | 0.160 |
Why?
|
| Cell Count | 1 | 2019 | 508 | 0.160 |
Why?
|
| Disease-Free Survival | 11 | 2018 | 10001 | 0.160 |
Why?
|
| Photons | 2 | 2019 | 507 | 0.160 |
Why?
|
| Radiation Oncologists | 1 | 2018 | 29 | 0.160 |
Why?
|
| Neoplasm Proteins | 2 | 2011 | 3230 | 0.160 |
Why?
|
| Biomedical Research | 2 | 2015 | 806 | 0.150 |
Why?
|
| Forecasting | 3 | 2018 | 694 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2020 | 7551 | 0.150 |
Why?
|
| Carcinoma | 2 | 2006 | 2578 | 0.150 |
Why?
|
| Models, Biological | 5 | 2010 | 3254 | 0.150 |
Why?
|
| Cultural Diversity | 1 | 2018 | 76 | 0.150 |
Why?
|
| Mice | 23 | 2016 | 34495 | 0.150 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2013 | 588 | 0.150 |
Why?
|
| Signal Transduction | 7 | 2016 | 11965 | 0.150 |
Why?
|
| Pyrrolidines | 2 | 1999 | 113 | 0.150 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2017 | 101 | 0.150 |
Why?
|
| Four-Dimensional Computed Tomography | 2 | 2016 | 226 | 0.150 |
Why?
|
| Smad4 Protein | 1 | 2018 | 196 | 0.150 |
Why?
|
| Lymphoma | 2 | 2016 | 1467 | 0.150 |
Why?
|
| Diffusion of Innovation | 2 | 2015 | 160 | 0.140 |
Why?
|
| Cell Line, Tumor | 11 | 2016 | 14551 | 0.140 |
Why?
|
| Information Systems | 1 | 2016 | 54 | 0.140 |
Why?
|
| Oncology Service, Hospital | 1 | 2016 | 48 | 0.140 |
Why?
|
| Radiotherapy, Adjuvant | 8 | 2017 | 2231 | 0.140 |
Why?
|
| Injections, Intraperitoneal | 3 | 2006 | 197 | 0.140 |
Why?
|
| Reproducibility of Results | 2 | 2017 | 6009 | 0.140 |
Why?
|
| Nomograms | 1 | 2018 | 313 | 0.130 |
Why?
|
| Professional Staff Committees | 1 | 2015 | 30 | 0.130 |
Why?
|
| Maximum Tolerated Dose | 3 | 2006 | 1290 | 0.130 |
Why?
|
| Cytokines | 2 | 2003 | 2809 | 0.130 |
Why?
|
| Societies, Medical | 4 | 2018 | 1335 | 0.130 |
Why?
|
| Carboplatin | 2 | 2017 | 823 | 0.130 |
Why?
|
| Prescriptions | 1 | 2015 | 65 | 0.130 |
Why?
|
| Protease Inhibitors | 2 | 2007 | 210 | 0.130 |
Why?
|
| Optics and Photonics | 3 | 2005 | 146 | 0.130 |
Why?
|
| Hospitals, High-Volume | 1 | 2016 | 77 | 0.130 |
Why?
|
| Minority Groups | 1 | 2018 | 322 | 0.130 |
Why?
|
| Interferon Type I | 1 | 2016 | 250 | 0.130 |
Why?
|
| Database Management Systems | 1 | 2015 | 63 | 0.130 |
Why?
|
| Free Radicals | 5 | 2003 | 62 | 0.130 |
Why?
|
| Male Urogenital Diseases | 1 | 2014 | 18 | 0.130 |
Why?
|
| Organizational Policy | 1 | 2015 | 73 | 0.130 |
Why?
|
| Ipilimumab | 1 | 2019 | 710 | 0.130 |
Why?
|
| Melanoma | 3 | 2018 | 5317 | 0.130 |
Why?
|
| Cricetinae | 6 | 2003 | 706 | 0.130 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 2015 | 126 | 0.130 |
Why?
|
| Certification | 1 | 2016 | 123 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 8 | 2005 | 5395 | 0.120 |
Why?
|
| ErbB Receptors | 5 | 2020 | 2295 | 0.120 |
Why?
|
| Spectrometry, Fluorescence | 2 | 2006 | 209 | 0.120 |
Why?
|
| Prognosis | 9 | 2018 | 21713 | 0.120 |
Why?
|
| Mice, Inbred BALB C | 4 | 2015 | 2314 | 0.120 |
Why?
|
| Philadelphia | 1 | 2014 | 38 | 0.120 |
Why?
|
| Organizational Culture | 1 | 2015 | 106 | 0.120 |
Why?
|
| Washington | 1 | 2014 | 70 | 0.120 |
Why?
|
| DNA Damage | 4 | 2003 | 1954 | 0.120 |
Why?
|
| Pilot Projects | 3 | 2018 | 2803 | 0.120 |
Why?
|
| Cancer Pain | 1 | 2019 | 312 | 0.120 |
Why?
|
| Cytotoxins | 1 | 1994 | 66 | 0.120 |
Why?
|
| Tissue Distribution | 4 | 2012 | 875 | 0.120 |
Why?
|
| Biological Science Disciplines | 1 | 2013 | 9 | 0.120 |
Why?
|
| Hypoxia | 2 | 2008 | 443 | 0.120 |
Why?
|
| Government Regulation | 1 | 2014 | 67 | 0.120 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 2013 | 15 | 0.120 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2009 | 503 | 0.120 |
Why?
|
| Workflow | 1 | 2015 | 275 | 0.120 |
Why?
|
| Prospective Studies | 10 | 2019 | 12873 | 0.120 |
Why?
|
| Health Services Needs and Demand | 1 | 2016 | 244 | 0.120 |
Why?
|
| Necrosis | 3 | 2006 | 580 | 0.120 |
Why?
|
| International Classification of Diseases | 1 | 2014 | 83 | 0.120 |
Why?
|
| Mesoporphyrins | 2 | 2003 | 3 | 0.120 |
Why?
|
| Capillary Leak Syndrome | 2 | 2003 | 14 | 0.120 |
Why?
|
| Deferoxamine | 3 | 1994 | 28 | 0.120 |
Why?
|
| T-Lymphocytes | 2 | 2018 | 3869 | 0.120 |
Why?
|
| Comparative Effectiveness Research | 1 | 2014 | 126 | 0.120 |
Why?
|
| Electron Spin Resonance Spectroscopy | 6 | 2000 | 62 | 0.110 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2018 | 406 | 0.110 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2015 | 278 | 0.110 |
Why?
|
| Health Services Research | 1 | 2015 | 233 | 0.110 |
Why?
|
| Clinical Coding | 1 | 2013 | 28 | 0.110 |
Why?
|
| Immune System | 1 | 2015 | 279 | 0.110 |
Why?
|
| Triacetoneamine-N-Oxyl | 1 | 1992 | 1 | 0.110 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2020 | 882 | 0.110 |
Why?
|
| Antigens, Surface | 1 | 2013 | 295 | 0.110 |
Why?
|
| Neoplasms, Second Primary | 2 | 2018 | 1350 | 0.110 |
Why?
|
| Carcinoma, Lobular | 1 | 2016 | 611 | 0.110 |
Why?
|
| Job Satisfaction | 1 | 2013 | 122 | 0.110 |
Why?
|
| Cell Line | 8 | 2003 | 5114 | 0.110 |
Why?
|
| Radiometry | 5 | 2014 | 980 | 0.110 |
Why?
|
| Peptide Fragments | 1 | 2018 | 1271 | 0.110 |
Why?
|
| Neutrophils | 1 | 1997 | 835 | 0.110 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2013 | 665 | 0.100 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2017 | 925 | 0.100 |
Why?
|
| Age Factors | 3 | 2019 | 5377 | 0.100 |
Why?
|
| Nuclear Power Plants | 1 | 2011 | 1 | 0.100 |
Why?
|
| Transcription Factor CHOP | 1 | 2011 | 25 | 0.100 |
Why?
|
| Radioactive Hazard Release | 1 | 2011 | 5 | 0.100 |
Why?
|
| Etoposide | 1 | 1993 | 870 | 0.100 |
Why?
|
| Retrospective Studies | 15 | 2020 | 37905 | 0.100 |
Why?
|
| Delphi Technique | 1 | 2012 | 210 | 0.100 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2011 | 60 | 0.100 |
Why?
|
| Immunomodulation | 3 | 2019 | 242 | 0.100 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2017 | 1648 | 0.100 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 4971 | 0.100 |
Why?
|
| Quality of Health Care | 1 | 2016 | 621 | 0.100 |
Why?
|
| Research | 1 | 2013 | 415 | 0.100 |
Why?
|
| CTLA-4 Antigen | 1 | 2015 | 657 | 0.100 |
Why?
|
| Anticarcinogenic Agents | 2 | 2003 | 362 | 0.100 |
Why?
|
| Singlet Oxygen | 1 | 2010 | 8 | 0.090 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2011 | 205 | 0.090 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2016 | 1016 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2018 | 15862 | 0.090 |
Why?
|
| Nanotechnology | 1 | 2011 | 137 | 0.090 |
Why?
|
| Risk Factors | 5 | 2018 | 17523 | 0.090 |
Why?
|
| Hemibody Irradiation | 1 | 2009 | 1 | 0.090 |
Why?
|
| Radiology | 1 | 2016 | 434 | 0.090 |
Why?
|
| Oxidation-Reduction | 5 | 2003 | 717 | 0.090 |
Why?
|
| Patient Education as Topic | 2 | 2012 | 748 | 0.090 |
Why?
|
| Ovarian Neoplasms | 5 | 2006 | 4638 | 0.090 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2015 | 840 | 0.090 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2016 | 1048 | 0.090 |
Why?
|
| Lymphatic Irradiation | 1 | 2010 | 133 | 0.090 |
Why?
|
| Disasters | 1 | 2011 | 107 | 0.090 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2016 | 1216 | 0.090 |
Why?
|
| Gastrointestinal Diseases | 1 | 2014 | 589 | 0.090 |
Why?
|
| Fibrosarcoma | 3 | 2010 | 135 | 0.090 |
Why?
|
| Positron-Emission Tomography | 5 | 2020 | 2173 | 0.090 |
Why?
|
| Breast Neoplasms | 5 | 2016 | 15694 | 0.080 |
Why?
|
| Hippocampus | 1 | 1995 | 915 | 0.080 |
Why?
|
| Heart Rate | 2 | 2004 | 737 | 0.080 |
Why?
|
| Incidence | 3 | 2021 | 5673 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2018 | 3251 | 0.080 |
Why?
|
| Glioma | 2 | 2014 | 1963 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 5 | 2007 | 2054 | 0.080 |
Why?
|
| Quality Indicators, Health Care | 1 | 2012 | 348 | 0.080 |
Why?
|
| Down-Regulation | 3 | 2007 | 2074 | 0.080 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2009 | 376 | 0.080 |
Why?
|
| Radiotherapy, Conformal | 3 | 2016 | 902 | 0.080 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2008 | 61 | 0.080 |
Why?
|
| Radiation Dosage | 3 | 2016 | 1014 | 0.080 |
Why?
|
| Cohort Studies | 5 | 2018 | 9244 | 0.080 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2011 | 436 | 0.080 |
Why?
|
| Patient Participation | 1 | 2012 | 446 | 0.080 |
Why?
|
| B7-H1 Antigen | 1 | 2015 | 1022 | 0.080 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2018 | 1763 | 0.080 |
Why?
|
| Spectrophotometry | 2 | 2004 | 82 | 0.080 |
Why?
|
| Software | 1 | 2015 | 1321 | 0.080 |
Why?
|
| Geriatric Assessment | 1 | 2009 | 275 | 0.080 |
Why?
|
| Feasibility Studies | 4 | 2019 | 2292 | 0.080 |
Why?
|
| Patient Compliance | 1 | 2012 | 667 | 0.080 |
Why?
|
| Regional Blood Flow | 2 | 2006 | 276 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 7702 | 0.080 |
Why?
|
| Genes, ras | 3 | 2005 | 667 | 0.080 |
Why?
|
| Intraoperative Care | 2 | 2012 | 259 | 0.080 |
Why?
|
| Thymoma | 1 | 2011 | 246 | 0.080 |
Why?
|
| Neoadjuvant Therapy | 4 | 2018 | 4975 | 0.070 |
Why?
|
| Esophageal Neoplasms | 1 | 2001 | 3168 | 0.070 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 7222 | 0.070 |
Why?
|
| Logistic Models | 1 | 2014 | 3441 | 0.070 |
Why?
|
| Radiopharmaceuticals | 1 | 2012 | 1301 | 0.070 |
Why?
|
| Budgets | 2 | 2019 | 25 | 0.070 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2014 | 962 | 0.070 |
Why?
|
| Scattering, Radiation | 2 | 2019 | 316 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2016 | 3890 | 0.070 |
Why?
|
| Eye Neoplasms | 1 | 2009 | 247 | 0.070 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 2576 | 0.070 |
Why?
|
| Cause of Death | 2 | 2015 | 752 | 0.070 |
Why?
|
| Sunburn | 1 | 2006 | 35 | 0.070 |
Why?
|
| Peritoneum | 1 | 2007 | 150 | 0.070 |
Why?
|
| Infusions, Intravenous | 3 | 2004 | 1382 | 0.070 |
Why?
|
| Biophysical Phenomena | 1 | 2005 | 112 | 0.070 |
Why?
|
| Whole-Body Irradiation | 2 | 2000 | 307 | 0.070 |
Why?
|
| Thymus Neoplasms | 1 | 2011 | 400 | 0.070 |
Why?
|
| Low-Level Light Therapy | 1 | 2005 | 24 | 0.070 |
Why?
|
| Biophysics | 1 | 2005 | 111 | 0.070 |
Why?
|
| Proteasome Inhibitors | 1 | 2007 | 231 | 0.070 |
Why?
|
| Postoperative Care | 1 | 2009 | 739 | 0.070 |
Why?
|
| Fatal Outcome | 2 | 2014 | 829 | 0.070 |
Why?
|
| Deoxycytidine | 2 | 2018 | 1353 | 0.070 |
Why?
|
| Rabbits | 1 | 2007 | 957 | 0.070 |
Why?
|
| Young Adult | 6 | 2020 | 21445 | 0.060 |
Why?
|
| Mice, SCID | 1 | 2009 | 1869 | 0.060 |
Why?
|
| Organ Specificity | 1 | 2006 | 699 | 0.060 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2010 | 674 | 0.060 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2005 | 83 | 0.060 |
Why?
|
| Protons | 3 | 2017 | 473 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2008 | 1678 | 0.060 |
Why?
|
| Hair | 1 | 2004 | 42 | 0.060 |
Why?
|
| Oxygen Consumption | 2 | 2010 | 401 | 0.060 |
Why?
|
| Edema | 1 | 2006 | 267 | 0.060 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2007 | 986 | 0.060 |
Why?
|
| Neoplasms, Radiation-Induced | 4 | 2011 | 388 | 0.060 |
Why?
|
| Administration, Topical | 1 | 2004 | 257 | 0.060 |
Why?
|
| Research Support as Topic | 2 | 2015 | 122 | 0.060 |
Why?
|
| Body Temperature | 1 | 2004 | 158 | 0.060 |
Why?
|
| Internship and Residency | 1 | 2015 | 1375 | 0.060 |
Why?
|
| Kidney | 3 | 2002 | 2146 | 0.060 |
Why?
|
| Superoxides | 3 | 1994 | 211 | 0.060 |
Why?
|
| Neoplasm Transplantation | 4 | 2003 | 1519 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2009 | 1533 | 0.060 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2003 | 82 | 0.060 |
Why?
|
| Pleural Cavity | 1 | 2003 | 25 | 0.060 |
Why?
|
| Cancer Vaccines | 1 | 2009 | 697 | 0.060 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2003 | 57 | 0.060 |
Why?
|
| Advisory Committees | 2 | 2015 | 203 | 0.060 |
Why?
|
| Clinical Protocols | 1 | 2005 | 467 | 0.060 |
Why?
|
| Reactive Oxygen Species | 2 | 1999 | 987 | 0.060 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2003 | 116 | 0.060 |
Why?
|
| Phantoms, Imaging | 2 | 2006 | 1271 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2011 | 8873 | 0.060 |
Why?
|
| Qualitative Research | 2 | 2018 | 556 | 0.050 |
Why?
|
| Intraoperative Period | 1 | 2003 | 246 | 0.050 |
Why?
|
| Comorbidity | 1 | 2009 | 2352 | 0.050 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 4557 | 0.050 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2011 | 1724 | 0.050 |
Why?
|
| Lactams | 1 | 2002 | 24 | 0.050 |
Why?
|
| Intestine, Large | 1 | 2002 | 28 | 0.050 |
Why?
|
| Diarrhea | 1 | 2006 | 686 | 0.050 |
Why?
|
| Lactones | 1 | 2002 | 94 | 0.050 |
Why?
|
| Depsipeptides | 1 | 2002 | 78 | 0.050 |
Why?
|
| Drugs, Investigational | 1 | 2003 | 135 | 0.050 |
Why?
|
| Surveys and Questionnaires | 3 | 2019 | 5687 | 0.050 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2009 | 1248 | 0.050 |
Why?
|
| Peptides, Cyclic | 1 | 2002 | 139 | 0.050 |
Why?
|
| Mouth Mucosa | 1 | 2002 | 216 | 0.050 |
Why?
|
| Research Design | 3 | 2018 | 1544 | 0.050 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2014 | 2341 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2015 | 1062 | 0.050 |
Why?
|
| Capacity Building | 1 | 2020 | 30 | 0.050 |
Why?
|
| Stomatitis | 1 | 2002 | 183 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2017 | 833 | 0.050 |
Why?
|
| Hematologic Diseases | 1 | 2002 | 242 | 0.050 |
Why?
|
| Quinolones | 1 | 2001 | 160 | 0.050 |
Why?
|
| Vomiting | 1 | 2002 | 354 | 0.050 |
Why?
|
| Benzodiazepines | 1 | 2001 | 170 | 0.050 |
Why?
|
| Cesium Radioisotopes | 1 | 2000 | 39 | 0.050 |
Why?
|
| Molecular Probes | 1 | 2000 | 72 | 0.050 |
Why?
|
| Nausea | 1 | 2002 | 525 | 0.050 |
Why?
|
| Skin Temperature | 1 | 1999 | 32 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2016 | 5178 | 0.040 |
Why?
|
| In Vitro Techniques | 3 | 2004 | 1618 | 0.040 |
Why?
|
| Swine, Miniature | 1 | 1999 | 67 | 0.040 |
Why?
|
| Mice, Nude | 5 | 2009 | 4307 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2003 | 726 | 0.040 |
Why?
|
| Nitroimidazoles | 1 | 2000 | 100 | 0.040 |
Why?
|
| Sarcoma, Experimental | 1 | 1999 | 68 | 0.040 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2001 | 295 | 0.040 |
Why?
|
| Tachycardia | 1 | 1999 | 70 | 0.040 |
Why?
|
| International Cooperation | 1 | 2020 | 323 | 0.040 |
Why?
|
| Drug Interactions | 2 | 2007 | 553 | 0.040 |
Why?
|
| Skin Diseases | 1 | 2002 | 349 | 0.040 |
Why?
|
| Gamma Rays | 1 | 2000 | 242 | 0.040 |
Why?
|
| Abdomen | 1 | 2001 | 332 | 0.040 |
Why?
|
| Cranial Irradiation | 1 | 2001 | 315 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 4988 | 0.040 |
Why?
|
| Vascular Resistance | 1 | 1999 | 200 | 0.040 |
Why?
|
| Resource Allocation | 1 | 2019 | 67 | 0.040 |
Why?
|
| Radiography | 2 | 2018 | 1904 | 0.040 |
Why?
|
| Treatment Failure | 2 | 2017 | 1391 | 0.040 |
Why?
|
| Area Under Curve | 2 | 2015 | 700 | 0.040 |
Why?
|
| Biopsy | 1 | 2006 | 3443 | 0.040 |
Why?
|
| Neoplasm Grading | 2 | 2014 | 1742 | 0.040 |
Why?
|
| Efficiency | 1 | 2019 | 99 | 0.040 |
Why?
|
| Risk Assessment | 3 | 2012 | 6869 | 0.040 |
Why?
|
| Vasodilator Agents | 1 | 1999 | 219 | 0.040 |
Why?
|
| Employment | 1 | 2019 | 129 | 0.040 |
Why?
|
| Leucovorin | 1 | 2018 | 332 | 0.040 |
Why?
|
| Computer Simulation | 2 | 2016 | 1529 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2020 | 441 | 0.040 |
Why?
|
| Emotional Intelligence | 1 | 2017 | 14 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2004 | 1265 | 0.040 |
Why?
|
| Hypotension | 1 | 1999 | 210 | 0.040 |
Why?
|
| Sexism | 1 | 2018 | 51 | 0.040 |
Why?
|
| Spouses | 1 | 2019 | 134 | 0.040 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2019 | 107 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2020 | 574 | 0.040 |
Why?
|
| Cricetulus | 2 | 1994 | 205 | 0.040 |
Why?
|
| Respiratory Burst | 1 | 1997 | 23 | 0.040 |
Why?
|
| Neutrophil Activation | 1 | 1997 | 34 | 0.040 |
Why?
|
| Clinical Competence | 2 | 2016 | 1270 | 0.040 |
Why?
|
| Racism | 1 | 2018 | 50 | 0.040 |
Why?
|
| Peritoneal Cavity | 1 | 1997 | 56 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 3472 | 0.040 |
Why?
|
| Immunity | 1 | 2019 | 342 | 0.040 |
Why?
|
| Pemetrexed | 1 | 2016 | 102 | 0.040 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 5112 | 0.040 |
Why?
|
| Radiation Monitoring | 1 | 2016 | 49 | 0.040 |
Why?
|
| Anorexia | 1 | 2017 | 143 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2010 | 208 | 0.040 |
Why?
|
| Utilization Review | 1 | 2016 | 48 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 2 | 2018 | 1547 | 0.030 |
Why?
|
| Bridged-Ring Compounds | 1 | 2016 | 183 | 0.030 |
Why?
|
| Green Fluorescent Proteins | 1 | 2018 | 694 | 0.030 |
Why?
|
| Leadership | 1 | 2019 | 254 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2018 | 497 | 0.030 |
Why?
|
| Plasmacytoma | 1 | 1997 | 111 | 0.030 |
Why?
|
| Piperidines | 1 | 2001 | 1035 | 0.030 |
Why?
|
| Fluorescent Dyes | 1 | 2018 | 459 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2019 | 1323 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2018 | 565 | 0.030 |
Why?
|
| Calreticulin | 1 | 2016 | 74 | 0.030 |
Why?
|
| Career Choice | 1 | 2018 | 232 | 0.030 |
Why?
|
| Ions | 1 | 2015 | 53 | 0.030 |
Why?
|
| Mucin-1 | 1 | 2016 | 127 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2019 | 554 | 0.030 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2016 | 235 | 0.030 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2016 | 222 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 1999 | 644 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2016 | 221 | 0.030 |
Why?
|
| Catalase | 2 | 1994 | 70 | 0.030 |
Why?
|
| Microelectrodes | 1 | 1995 | 52 | 0.030 |
Why?
|
| Swine | 1 | 1999 | 1541 | 0.030 |
Why?
|
| Technology, Radiologic | 1 | 2015 | 80 | 0.030 |
Why?
|
| Medical Audit | 1 | 2016 | 188 | 0.030 |
Why?
|
| Streptonigrin | 1 | 1994 | 4 | 0.030 |
Why?
|
| Guinea Pigs | 1 | 1995 | 241 | 0.030 |
Why?
|
| Anthracyclines | 1 | 2016 | 331 | 0.030 |
Why?
|
| Cell Membrane | 2 | 2016 | 850 | 0.030 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2018 | 690 | 0.030 |
Why?
|
| tert-Butylhydroperoxide | 1 | 1994 | 6 | 0.030 |
Why?
|
| Peroxides | 1 | 1994 | 12 | 0.030 |
Why?
|
| Pyridines | 1 | 2001 | 1244 | 0.030 |
Why?
|
| Program Development | 1 | 2016 | 261 | 0.030 |
Why?
|
| Electrodes | 2 | 2004 | 116 | 0.030 |
Why?
|
| Models, Statistical | 2 | 2016 | 1171 | 0.030 |
Why?
|
| Enzyme Assays | 1 | 2014 | 22 | 0.030 |
Why?
|
| Electrophysiology | 1 | 1995 | 333 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2018 | 1944 | 0.030 |
Why?
|
| Heart | 2 | 2019 | 1223 | 0.030 |
Why?
|
| Chordoma | 1 | 2016 | 163 | 0.030 |
Why?
|
| Evoked Potentials | 1 | 1995 | 190 | 0.030 |
Why?
|
| Brachytherapy | 1 | 2001 | 977 | 0.030 |
Why?
|
| Personnel Turnover | 1 | 2013 | 11 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2016 | 297 | 0.030 |
Why?
|
| Needles | 2 | 2004 | 107 | 0.030 |
Why?
|
| Prostate-Specific Antigen | 2 | 2008 | 993 | 0.030 |
Why?
|
| Glutathione | 2 | 1993 | 368 | 0.030 |
Why?
|
| Methionine Sulfoximine | 1 | 1993 | 2 | 0.030 |
Why?
|
| Education, Medical, Continuing | 1 | 2016 | 251 | 0.030 |
Why?
|
| Staff Development | 1 | 2013 | 61 | 0.030 |
Why?
|
| Documentation | 1 | 2015 | 207 | 0.030 |
Why?
|
| Pain Management | 1 | 2019 | 668 | 0.030 |
Why?
|
| Immunohistochemistry | 3 | 2012 | 7548 | 0.030 |
Why?
|
| Mutation | 2 | 2015 | 15179 | 0.030 |
Why?
|
| Deglutition Disorders | 1 | 2017 | 447 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2018 | 1021 | 0.030 |
Why?
|
| HLA Antigens | 1 | 2016 | 546 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 1052 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2016 | 597 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 2 | 2012 | 3981 | 0.030 |
Why?
|
| Taxoids | 1 | 2016 | 967 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2018 | 795 | 0.030 |
Why?
|
| Risk | 1 | 2017 | 1972 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 582 | 0.030 |
Why?
|
| Markov Chains | 1 | 2013 | 175 | 0.030 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 1992 | 71 | 0.030 |
Why?
|
| 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt | 1 | 1992 | 2 | 0.030 |
Why?
|
| Teaching | 1 | 2014 | 243 | 0.030 |
Why?
|
| Respiration | 1 | 2015 | 447 | 0.030 |
Why?
|
| Cell Division | 1 | 1997 | 2489 | 0.030 |
Why?
|
| Endotoxins | 1 | 1992 | 96 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2013 | 226 | 0.030 |
Why?
|
| Kinetics | 2 | 2010 | 2049 | 0.030 |
Why?
|
| Altruism | 1 | 2012 | 34 | 0.030 |
Why?
|
| Aging | 1 | 2020 | 1582 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2014 | 3821 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 1992 | 231 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 1085 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 2000 | 3033 | 0.030 |
Why?
|
| Laparoscopy | 1 | 2001 | 1225 | 0.030 |
Why?
|
| Molecular Imaging | 1 | 2013 | 185 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 1993 | 566 | 0.030 |
Why?
|
| ROC Curve | 1 | 2015 | 1183 | 0.030 |
Why?
|
| Lymphatic Metastasis | 3 | 2011 | 4844 | 0.030 |
Why?
|
| Movement | 1 | 2015 | 556 | 0.030 |
Why?
|
| Education, Medical | 1 | 2016 | 331 | 0.030 |
Why?
|
| Earthquakes | 1 | 2011 | 5 | 0.030 |
Why?
|
| Reimbursement, Incentive | 1 | 2012 | 53 | 0.030 |
Why?
|
| Chernobyl Nuclear Accident | 1 | 2011 | 12 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 992 | 0.030 |
Why?
|
| Heterografts | 1 | 2014 | 733 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2016 | 585 | 0.020 |
Why?
|
| Activating Transcription Factor 4 | 1 | 2011 | 73 | 0.020 |
Why?
|
| Fatigue | 1 | 2017 | 1239 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2017 | 1656 | 0.020 |
Why?
|
| Thoracic Cavity | 1 | 2010 | 10 | 0.020 |
Why?
|
| Japan | 1 | 2011 | 227 | 0.020 |
Why?
|
| Unfolded Protein Response | 1 | 2011 | 115 | 0.020 |
Why?
|
| Metals | 1 | 1991 | 155 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2015 | 673 | 0.020 |
Why?
|
| Diffusion | 1 | 2010 | 88 | 0.020 |
Why?
|
| Transplantation, Heterologous | 2 | 2005 | 1082 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 1997 | 5637 | 0.020 |
Why?
|
| Copper | 1 | 1991 | 165 | 0.020 |
Why?
|
| Organometallic Compounds | 1 | 1991 | 191 | 0.020 |
Why?
|
| Mastectomy | 1 | 2016 | 1534 | 0.020 |
Why?
|
| Self Report | 1 | 2013 | 756 | 0.020 |
Why?
|
| Review Literature as Topic | 1 | 2010 | 71 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2017 | 2218 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2018 | 2086 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 2 | 2004 | 769 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2015 | 1694 | 0.020 |
Why?
|
| Patient Preference | 1 | 2012 | 218 | 0.020 |
Why?
|
| Whole Body Imaging | 1 | 2010 | 114 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2016 | 2450 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2015 | 1459 | 0.020 |
Why?
|
| Urinary Bladder | 1 | 2012 | 575 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2016 | 1586 | 0.020 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2000 | 1833 | 0.020 |
Why?
|
| Physicians | 1 | 2017 | 882 | 0.020 |
Why?
|
| Bone Marrow | 1 | 1997 | 2358 | 0.020 |
Why?
|
| Motivation | 1 | 2012 | 499 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2015 | 1146 | 0.020 |
Why?
|
| Adolescent | 3 | 2015 | 31252 | 0.020 |
Why?
|
| Curriculum | 1 | 2013 | 860 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2009 | 388 | 0.020 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2015 | 1283 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 1993 | 1910 | 0.020 |
Why?
|
| Lung | 1 | 2019 | 3151 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 2003 | 3578 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2016 | 1443 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2003 | 5542 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 6207 | 0.020 |
Why?
|
| Protein Denaturation | 1 | 2007 | 70 | 0.020 |
Why?
|
| Quality of Life | 2 | 2013 | 4532 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 2010 | 330 | 0.020 |
Why?
|
| Phosphorylation | 2 | 2007 | 4804 | 0.020 |
Why?
|
| Epilepsy | 1 | 1995 | 883 | 0.020 |
Why?
|
| Stem Cells | 1 | 2013 | 1213 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2014 | 3101 | 0.020 |
Why?
|
| Protein Folding | 1 | 2007 | 281 | 0.020 |
Why?
|
| Acute Disease | 1 | 2011 | 2422 | 0.020 |
Why?
|
| Prevalence | 1 | 2013 | 3260 | 0.020 |
Why?
|
| Sp1 Transcription Factor | 1 | 2006 | 188 | 0.020 |
Why?
|
| DNA Repair | 1 | 2013 | 1872 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 4549 | 0.020 |
Why?
|
| Random Allocation | 1 | 2006 | 703 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2014 | 6100 | 0.020 |
Why?
|
| Carbocyanines | 1 | 2004 | 41 | 0.020 |
Why?
|
| Myocardium | 1 | 1991 | 1313 | 0.020 |
Why?
|
| Quinazolines | 1 | 2009 | 923 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2004 | 300 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2004 | 2488 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2007 | 589 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 6942 | 0.010 |
Why?
|
| Laryngeal Neoplasms | 1 | 2007 | 518 | 0.010 |
Why?
|
| Genes, erbB-1 | 1 | 2004 | 101 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 4314 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 5539 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 2011 | 1959 | 0.010 |
Why?
|
| Infusions, Parenteral | 1 | 2003 | 191 | 0.010 |
Why?
|
| Amifostine | 1 | 2003 | 97 | 0.010 |
Why?
|
| Genes, erbB-2 | 1 | 2004 | 229 | 0.010 |
Why?
|
| DNA | 1 | 1991 | 2693 | 0.010 |
Why?
|
| Genomics | 1 | 2013 | 2738 | 0.010 |
Why?
|
| Mouth Neoplasms | 1 | 2007 | 713 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2015 | 8223 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2005 | 1313 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2003 | 629 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2003 | 573 | 0.010 |
Why?
|
| Critical Pathways | 1 | 2003 | 149 | 0.010 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2003 | 243 | 0.010 |
Why?
|
| Models, Chemical | 1 | 2002 | 186 | 0.010 |
Why?
|
| Biomarkers | 1 | 2013 | 5047 | 0.010 |
Why?
|
| Appendiceal Neoplasms | 1 | 2004 | 234 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2003 | 445 | 0.010 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2001 | 157 | 0.010 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2004 | 297 | 0.010 |
Why?
|
| Blotting, Northern | 2 | 1992 | 682 | 0.010 |
Why?
|
| Benzimidazoles | 1 | 2004 | 428 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2004 | 1764 | 0.010 |
Why?
|
| Intestine, Small | 1 | 2004 | 499 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2003 | 604 | 0.010 |
Why?
|
| Brain | 1 | 2013 | 4113 | 0.010 |
Why?
|
| Laparotomy | 1 | 2001 | 211 | 0.010 |
Why?
|
| Infant | 1 | 2015 | 13310 | 0.010 |
Why?
|
| Respiration, Artificial | 1 | 2003 | 577 | 0.010 |
Why?
|
| Extremities | 1 | 2001 | 303 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2003 | 803 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2015 | 16273 | 0.010 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2007 | 1105 | 0.010 |
Why?
|
| Neutropenia | 1 | 2003 | 968 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 2001 | 577 | 0.010 |
Why?
|
| Blood Vessels | 1 | 1999 | 217 | 0.010 |
Why?
|
| Intensive Care Units | 1 | 2003 | 717 | 0.010 |
Why?
|
| Cell Separation | 1 | 2000 | 612 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2002 | 785 | 0.010 |
Why?
|
| Body Weight | 1 | 2003 | 1293 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 2003 | 846 | 0.010 |
Why?
|
| Spinal Cord | 1 | 2001 | 690 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2004 | 1390 | 0.010 |
Why?
|
| Binding Sites | 1 | 2000 | 2171 | 0.010 |
Why?
|
| Mitochondria | 1 | 2003 | 1282 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2003 | 1756 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2003 | 1823 | 0.010 |
Why?
|
| Quinones | 1 | 1994 | 21 | 0.010 |
Why?
|
| NADH Dehydrogenase | 1 | 1994 | 15 | 0.010 |
Why?
|
| Proteins | 1 | 2003 | 1963 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2003 | 4892 | 0.010 |
Why?
|
| Child | 1 | 2015 | 29154 | 0.010 |
Why?
|
| Buthionine Sulfoximine | 1 | 1993 | 41 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 1992 | 156 | 0.010 |
Why?
|
| Microtubules | 1 | 1993 | 270 | 0.010 |
Why?
|
| Hydroxides | 1 | 1991 | 8 | 0.010 |
Why?
|
| Hydroxyl Radical | 1 | 1991 | 19 | 0.010 |
Why?
|
| Chelating Agents | 1 | 1992 | 127 | 0.010 |
Why?
|
| Blood Proteins | 1 | 1992 | 294 | 0.010 |
Why?
|
| Phenotype | 1 | 2002 | 6295 | 0.010 |
Why?
|
| Mortality | 1 | 1992 | 343 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1991 | 299 | 0.010 |
Why?
|
| Arginine | 1 | 1992 | 500 | 0.010 |
Why?
|
| Iron | 1 | 1992 | 376 | 0.010 |
Why?
|
| Intestines | 1 | 1992 | 686 | 0.000 |
Why?
|
| Cell Cycle | 1 | 1993 | 2084 | 0.000 |
Why?
|
| Transcription, Genetic | 1 | 1992 | 3154 | 0.000 |
Why?
|
| Gene Expression | 1 | 1991 | 3570 | 0.000 |
Why?
|
| Rats | 1 | 1991 | 6086 | 0.000 |
Why?
|
| RNA, Messenger | 1 | 1991 | 6150 | 0.000 |
Why?
|